A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/2011
10/20/2011	US20110256162 Plasmids coding for p185neu protein sequence variants and therapeutic uses thereof
10/20/2011	US20110256161 Methods for enhancing immune response
10/20/2011	US20110256158 Novel use of an il-12 receptor splice variant and molecular assay to quantify expression thereof
10/20/2011	US20110256157 Pyrrolobenzodiazepines and conjugates thereof
10/20/2011	US20110256156 TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY
10/20/2011	US20110256155 Methods to molecularly characterize circulating tumor cells
10/20/2011	US20110256154 Anti-erbb3 antibodies
10/20/2011	US20110256153 CD37-Binding Molecules and Immunoconjugates Thereof
10/20/2011	US20110256152 Methods Of Treating And Preventing Glucose Toxicity
10/20/2011	US20110256151 Antibodies to human il-1beta
10/20/2011	US20110256150 Modulation of Axon Degeneration
10/20/2011	US20110256149 Antibody formulation
10/20/2011	US20110256148 Methods for Treating Hypercholesterolemia Using Antibodies to PCSK9
10/20/2011	US20110256147 Diagnostic and treatment methods for cancer based on immune inhibitors
10/20/2011	US20110256146 Neuropilin antagonists
10/20/2011	US20110256145 Connective Tissue Growth Factor-3 (CTGF-3)
10/20/2011	US20110256144 Pharmaceutical composition for treatment and prevention of cancers
10/20/2011	US20110256143 FDF03 Antibodies and uses thereof
10/20/2011	US20110256142 Novel methods and antibodies for treating cancer
10/20/2011	US20110256141 Monoclonal Antibodies Specific to the Fusion Peptide From Hemagglutinin From Influenza A Viruses and Uses Thereof
10/20/2011	US20110256140 Anti-hcv monoclonal antibody as a medicament for the theraputic treatment and prevention of hcv infections
10/20/2011	US20110256139 Therapeutic Uses Of Monoclonal Antibodies To The Angiotensin-II Type 1 Receptor
10/20/2011	US20110256138 Amyloid-beta binding proteins
10/20/2011	US20110256137 Pharmaceutical composition comprising a bispecific antibody for epcam
10/20/2011	US20110256136 Complement Inhibitors For Treatment Of Injury From Intracerebral Hemorrhage
10/20/2011	US20110256135 Anti-nerve growth factor (ngf) antibody compositions
10/20/2011	US20110256134 Methods of treatment using anti-oxidized ldl antibodies
10/20/2011	US20110256133 Anti-polyubiquitin antibodies and methods of use
10/20/2011	US20110256132 Myostatin binding proteins
10/20/2011	US20110256131 BLOCKERS OF LIGHT, LTalpha1beta2 AND LTalpha2beta1 OR ITS RECEPTOR LTbetaR FOR THE PREVENTION AND TREATMENT OF CHRONIC HEPATITIS AND OTHER LIVER DISEASES
10/20/2011	US20110256130 Methods of treating inflammatory disorders
10/20/2011	US20110256129 Apoptosis promoters
10/20/2011	US20110256128 Triazole compounds as ksp inhibitors
10/20/2011	US20110256127 Anti-lrp6 antibodies
10/20/2011	US20110256126 IL-17A/F Heterologous Polypeptides and Therapeutic Uses Thereof
10/20/2011	US20110256125 Materials and methods for improved immunoglycoproteins
10/20/2011	US20110256124 METHODS FOR IMPROVING THE BIOACTIVITY OF THERAPEUTIC IgE ANTIBODIES FOR THE TREATMENT OF DISEASE
10/20/2011	US20110256123 Methods and uses of leptin in immune modulation and hepatocellular carcinoma
10/20/2011	US20110256122 Polypeptides, antibody variable domains & antagonists
10/20/2011	US20110256121 Methods and kits for diagnosing or monitoring autoimmune and chronic inflammatory diseases
10/20/2011	US20110256098 Immunotherapy for chronic hepatitis c virus infection
10/20/2011	US20110256094 Methods and Compositions for Chlamydial Antigens for Diagnosis and Treatment of Chlamydial Infection and Disease
10/20/2011	US20110256093 Treating Disorders Associated with IL-20 Receptor-Mediated Signaling Pathway by Blocking IL-20 Receptor Activity
10/20/2011	US20110256092 Quinoline derivatives for modulating dna methylation
10/20/2011	US20110256091 Antibody-Targeted Cytokines for Therapy
10/20/2011	US20110256088 Targeted delivery of nucleic acids
10/20/2011	US20110256064 Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins
10/20/2011	US20110256063 Mex3c regulation and target to control obesity and diabetes
10/20/2011	US20110256061 Binding agents to the Integrin Alpha-11 subunit, and uses thereof
10/20/2011	US20110256060 Monoclonal antibody and its use for the identification of the oncofetal isoform of fibronectin (b-fn) for diagnosis or therpay
10/20/2011	US20110256059 Nanoparticulate systems prepared from anionic polymers
10/20/2011	US20110256054 Compositions and Methods for the Treatment and Prevention of Lens Fibrotic Diseases
10/20/2011	US20110256053 Multiple Signaling Pathways Induced by Hexavalent, Monospecific and Bispecific Antibodies for Enhanced Toxicity to B-Cell Lymphomas and Other Diseases
10/20/2011	CA2796205A1 Combination treatment with vegf-c antagonists
10/20/2011	CA2796197A1 Compositions comprising polyglutamic acid nanoparticles and polypeptides such as cd40 agonists
10/20/2011	CA2796083A1 Compositions and methods for treating copd exacerbation
10/20/2011	CA2796064A1 Treating disorders associated with il-20 receptor-mediated signaling pathway by blocking il-20 receptor activity
10/20/2011	CA2796055A1 Human fgf receptor and .beta.-klotho binding proteins
10/20/2011	CA2796053A1 Methods and compositions for inhibition of treg cells
10/20/2011	CA2796004A1 Method of vaccination
10/20/2011	CA2795953A1 Antibodies for the treatment of clostridium difficile-associated infection and disease
10/20/2011	CA2795947A1 Method for treating solid tumors
10/20/2011	CA2795886A1 Methods and compositions for improving implant osseointegration
10/20/2011	CA2795078A1 Proteins that bind pi16 and uses thereof
10/20/2011	CA2793503A1 Anti-polyubiquitin antibodies and methods of use
10/19/2011	EP2377932A1 ANTI-Siglec-15 ANTIBODY
10/19/2011	EP2377891A1 Diagnosis and treatment of cancer using anti-lgr7 antibody
10/19/2011	EP2377890A2 Antibodies
10/19/2011	EP2377889A2 Antibodies
10/19/2011	EP2377886A1 Antibody glycosylation in the variable region
10/19/2011	EP2377885A1 Method for producing comprehensive anti-surface antibody wherein the antigen used is a microorganism fixed by a protein crosslinking and fixation reagent
10/19/2011	EP2377880A2 Combination therapy of HIV fusion entry inhibitors targeting gp41
10/19/2011	EP2377879A1 N-terminal HPV E7 fusion proteins
10/19/2011	EP2377558A2 Composition for improving inflammatory disease using abh antigens
10/19/2011	EP2377555A2 Antibodies against vascular endothelial growth factor receptor-1
10/19/2011	EP2377554A1 Concentrated protein lyophilates, methods and uses
10/19/2011	EP2377553A1 Use of IL-1 antibodies for treating ophthalmic disorders
10/19/2011	EP2377552A2 Influenza vaccines with reduced amount of emulsion adjuvant
10/19/2011	EP2377551A2 Adjuvanted influenza vaccines including cytokine-inducing agents
10/19/2011	EP2377550A1 Heat treated bacterins, and emulsion vaccines prepared from such heat treated bacterins
10/19/2011	EP2377549A1 Use of IL-21 for treating viral infections
10/19/2011	EP2377548A2 Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
10/19/2011	EP2377547A1 Use of IL-21 as an antimicrobial agent
10/19/2011	EP2377517A2 Pharmaceutical composition containing an anionic drug, and a production method therefor
10/19/2011	EP2376654A2 Vaccines targeting cellular death receptors
10/19/2011	EP2376640A1 Methods and compositions for use of a coccidiosis vaccine
10/19/2011	EP2376639A1 Pcv 2-based methods and compositions for the treatment of pigs
10/19/2011	EP2376628A2 Production of influenza vaccines
10/19/2011	EP2376618A1 Compositions and methods for controlling disease in animals
10/19/2011	EP2376536A2 Remedies for pemphigus containing anti fas ligand antibodies
10/19/2011	EP2376535A1 Anti-pd-l1 antibodies and their use to enhance t-cell function
10/19/2011	EP2376533A1 Antibody formulation
10/19/2011	EP2376532A2 Organic compounds
10/19/2011	EP2376526A1 Modified streptococcus pneumoniae pneumolysin (ply) polypeptides
10/19/2011	EP2376523A1 Precipitation of biomolecules with negatively charged polymers
10/19/2011	EP2376126A2 Antagonists of il-6 to prevent or treat thrombosis
10/19/2011	EP2376122A2 Agent for prophylaxis or treatment of cancer
10/19/2011	EP2376121A1 Osteoarthritis treatment
10/19/2011	EP2376120A2 Use of dr6 and p75 antagonists to promote survival of cells of the nervous system
10/19/2011	EP2376119A1 Anti-hcv monoclonal antibody as a medicament for the therapeutic treatment and prevention of hcv infections

1 ... 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 ... 1823